AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06002295
Drug: Methylated Spirit
RxNorm normalized name: methylated spirits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After approval from the hospital ethical committee, neonates fulfilling inclusion and exclusion criteria were selected. Written informed consent was obtained from the parents. Full instructions to avoid confounding variables like maintaining temperature and hygiene of newborn, frequent diaper change, avoidance of herbal tonics and cow milk; are given to mothers.~In group A 4% chlorhexidine was applied generously over cord along with base of cord stump and surrounding skin thrice a day. In group B clean cotton swab dipped in methylated spirit was used to clean cord along with cord clamps and base thrice a day.
Trial: NCT04634409
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV.
Trial: NCT01872897
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 tablets as a single dose
Trial: NCT00586131
Drug: ammonium chloride or sodium citrate/citric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose dictated by changes in pH
Trial: NCT01093742
Drug: HM10560A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously administrate at 0 hour on Day 1
Trial: NCT01093742
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00405977
Drug: Physiologic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group and 1 ml per kg physiological saline. The infusion will be given with during 15 minutes.
Trial: NCT00133718
Drug: Combined lifestyle intervention and optimisation of pharmacological treatment
RxNorm normalized name: Betagen brand of Betamethasone and Gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. 6 months non-pharmacological treatment, 18 months with polypharmacy for glucose control (metformin, repaglinide/glimepiride, pioglitazone or insulin)~2. standard care
Trial: NCT01773512
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will be using rosuvastatin 40 mg
Trial: NCT00598559
Drug: IV Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 1: 1 g IV Acetaminophen every 6 hours administered for five days. Arm 2: 650 mg IV Acetaminophen every 4 hours administered for five days. Arm 3: The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.
Trial: NCT00434161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One bolus IV injection at 60 μg/kg/day of matched placebo on Days 6, 5 \& 4 (before-high dose chemotherapy) and on Days 0, 1 \& 2 (after-high dose chemotherapy).~Minimum of 4 days between pre-chemotherapy and post-transplantation dosing.
Trial: NCT00592852
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: capsules, dose range of 10mgQD - 60mgQD, given daily for 12 weeks
Trial: NCT04468971
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expicient
Trial: NCT00367315
Drug: Lumiracoxib
RxNorm normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00543361
Drug: MK0767
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of Treatment: 52 Weeks
Trial: NCT00543361
Drug: Comparator: placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of Treatment: 52 Weeks
Trial: NCT05869097
Drug: Trifluridine/Tipiracil
RxNorm normalized name: TRIFLURIDINE/TIPIRACIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days
Trial: NCT02916173
Drug: Recombinant Human Chorionic Gonadotrophin
RxNorm normalized name: Recombinant human chorionic gonadotrophin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 unit intramuscular
Trial: NCT04347187
Drug: Anticoagulants
RxNorm normalized name: ANTICOAGULANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral anticoagulants, dual or triple antithrombotic theraphy
Trial: NCT03785964
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic nirogacestat 50 mg tablet
Trial: NCT03744182
Drug: Placebo of HM15211
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A sterile, matching solution in pre-filled syringes
Trial: NCT00996866
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo group will receive sugar pills appearing similar to the vitamin D capsules.
Trial: NCT00671879
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet
Trial: NCT03448042
Drug: Runimotamab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Runimotamab will be administered via IV infusion until disease progression, intolerable toxicity, or any other discontinuation criteria are met.
Trial: NCT04545762
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously (IV)
Trial: NCT01001897
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 micrograms of misoprostol or placebo inserted buccally or vaginally prior to IUD insertion
Trial: NCT00287027
Drug: Risperdal Long Acting Injectable Antipsychotic Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02562768
Drug: LY3154207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02562768
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03397173
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid will be administered orally daily at 1 g/day three days prior to start azacitidine and then continues daily for a total of 28 days of each 28 day cycle. No dose modifications will be permitted during the treatment period.
Trial: NCT01336192
Drug: Best supportive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best supportive care
Trial: NCT00485433
Drug: SKY0402
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKY0402 given during hernia repair
Trial: NCT02755298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03664232
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a matching placebo orally twice daily for 12 weeks.
Trial: NCT00003520
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Stage IV Kidney Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT00909727
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet given orally q12h for up to 48 weeks
Trial: NCT02110420
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered once daily for up to 14 days depending on the Part of the study
Trial: NCT03788681
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01339910
Drug: Busulfan and Cyclophosphamide
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: (Bu/Cy)~* Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m\^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m\^2, respectively) on Days -7 to -4~* Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
Trial: NCT01339910
Drug: Cyclophosphamide and Total Body Irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Cy/TBI)~* TBI: 1200-1420 cGy on Days -7 to -4~* Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
Trial: NCT03622502
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 2.0 ng/ml)
Trial: NCT03622502
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline was infused over 10 min before end of the surgery
Trial: NCT02322879
Drug: First Treatment Period
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (duration: 14 days) Subjects will be randomized to receive either of the 2 interventions (4 grams of solid acetaminophen formulation for two weeks vs. 4 grams of solid acetaminophen formulation + 70 mg/kg/day of liquid propylene glycol)
Trial: NCT02322879
Drug: Second Treatment Period
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (duration: 14 days) At the end of the washout period, participants will receive the alternative intervention.
Trial: NCT03778996
Drug: Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral combination therapy for cancer
Trial: NCT00118300
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients also receive oral capecitabine twice daily 7 days a week in weeks 1-5 and 7-8. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.
Trial: NCT02386059
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: received normal saline, intravenously
Trial: NCT03400995
Drug: AK0529
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A solution containing 300 mg radiolabelled AK0529.
Trial: NCT03896685
Drug: Control arm MDR-TB regimen, designed according to latest WHO guidelines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control arm MDR-TB regimen, designed according to latest WHO guidelines (might include bedaquiline, delamanid, linezolid, clofazimine, or all of these drugs).
Trial: NCT00866788
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a single subcutaneous placebo injection on Day 0 of the study.
Trial: NCT04081337
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04485988
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of medication
Trial: NCT02491788
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00974493
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The trial protocol does not specify individual antibiotics, as the trial question is one of strategy (i.e. oral vs intravenous route) rather than individual antibiotics.~Within allocated strategy (i.e. oral or intravenous) antibiotics will be selected by a clinician with reference to the subject's clinical condition, microbiological data and local guidelines.
Trial: NCT03238742
Drug: Xuebijing Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100ml Xuebijing Injection every 12 hours for 5 days
Trial: NCT03238742
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200ml normal saline every 12 hours for 5 days
Trial: NCT03046992
Drug: YH25448
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Dose Escalation: YH25448 20mg\~320mg, PO~* Dose Expansion: YH25448 40mg\~240mg, PO~* Dose Extension: Recommended Dose 240mg of YH25448
Trial: NCT00772577
Drug: Aliskiren Hydrochlorothiazide
RxNorm normalized name: aliskiren / hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren HCTZ 150/12.5 mg: 1 week; Aliskiren HCTZ 300/25 mg: 7 weeks
Trial: NCT01891513
Drug: ACE inhibitor + exercise
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In addition to exercise training, participants will receive an initial perindopril dose of 2 mg/day which will be titrated to 4 mg/day.
Trial: NCT01891513
Drug: Thiazide diuretic + exercise
RxNorm normalized name: althiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In addition to exercise training, participants will receive an initial hydrochlorothiazide dose of 12.5 mg/day which will be titrated to 25 mg/day.
Trial: NCT03080987
Drug: JNJ-64179375 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenous (IV) infusion on Day 1.
Trial: NCT03080987
Drug: JNJ-64179375 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-64179375 1.0 mg/kg on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).
Trial: NCT03080987
Drug: JNJ-64179375 2.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-64179375 2.5 mg/kg IV infusion on Day 1.
Trial: NCT02688400
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02688400
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00389506
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02424305
Drug: LEO 43204 gel 0.018%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02424305
Drug: LEO 43204 gel 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02424305
Drug: LEO 43204 gel 0.037%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02151981
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomization to either Osimertinib or platinum-based doublet-chemotherapy on Day 1 of every 21d cycle in a 2:1 (Osimertinib:platinum-based doublet-chemotherapy) ratio
Trial: NCT04106219
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered IV.
Trial: NCT00195273
Drug: corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As per center practice. By day 8 prednisolone tapered to 20 mg/day; by day 30 to 15 mg/day; by day 60 to 10 mg/day; after 4 to 6 months to 5-7.5 mg/day
Trial: NCT02186873
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo.
Trial: NCT04875962
Drug: UCB0599
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive an assigned dosage regimen of UCB0599 during the Treatment Period.
Trial: NCT04875962
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive an assigned dosage regimen of Placebo during the Treatment Period to maintain the blinding.
Trial: NCT01484041
Drug: Aromatase Inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive one of the aromatase inhibitors either anastrozole 1 mg po daily, letrozole 2.5 mg po daily, or exemestane 25 mg po daily
Trial: NCT02372370
Drug: MAL Control.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention: Topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)).
Trial: NCT00867685
Drug: AZD2624
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 40 mg AZD2624 liquid suspension, PO
Trial: NCT00867685
Drug: AZD2624
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 40 mg AZD 2624 (2x20mg tablets), PO
Trial: NCT00161473
Drug: placebo (inert substance)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is an inert substance used as a standard comparator in clinical pharmacologic trials. Duration is 8 weeks.
Trial: NCT04342273
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered once daily at Day 1 through Day 7
Trial: NCT01635985
Drug: AZD5423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for injection, administered as intravenous infusion Corr to total dose of 250 µg AZD5423
Trial: NCT01635985
Drug: AZD5423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
Trial: NCT01635985
Drug: AZD5423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
Trial: NCT01635985
Drug: AZD5423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
Trial: NCT01635985
Drug: AZD5423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dry powder inhaled via New Dry Powder Inhaler, corr to approximately 200 µg lung deposited dose AZD5423
Trial: NCT00752323
Drug: aminolevulinic acid
RxNorm normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01894984
Drug: Oral atypical anti-psychotic
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study. Oral atypical anti-psychotic for example, olanzapine, risperidone, quetiapine etc will be administered as per Investigator's discretion.
Trial: NCT03835819
Drug: IMGN853
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirvetuximab soravtansine is an antibody-drug conjugate.
Trial: NCT02572583
Drug: Liugan Shuangjie Heji
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00877110
Drug: cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive combination chemotherapy with intravenous (IV) cyclophosphamide 70mg/kg/day (for patients with body weight\<70kg) or 2100mg/m2/day (for patients with body weight ≥70kg) for two days, IV vincristine 0.067mg/kg or 2mg/m2/day (lower of the two doses to be chosen; maximum 2mg) for one day, and IV topotecan 2.4 mg/m2/day for 3 days during their first cycle. If receiving a second and/or third cycle, the only chemotherapy patients will receive is cyclophosphamide at 50 mg/kg/day for 2 days. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor. On day +3, the patient will start daily infusion of 3F8 for 5 days. The treatment schedule may require minor adjustment by ±1 day as clinically indicated (e.g. due to PDH closure for holidays or due to inclement weather).
Trial: NCT00598702
Drug: IV Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target is 1 to 7 days of therapy with intravenous (IV) Acetaminophen (IV APAP) at a dose of 40 to 75 mg/kg body weight/day administered as an IV infusion (or by syringe pump) over 15 minutes and given every 4 to 6 hours as a scheduled dose
Trial: NCT02413372
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00258284
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
Trial: NCT03024814
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first group will receive acetaminophen as the following~1. Loading dose: 20 mg/kg in the first 12-24 hours To be diluted in D5W up to 3-5 ml and to be infused over 15 minutes.~2. Maintenance dose: 7.5 mg/kg after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days.
Trial: NCT03024814
Drug: Dextrose 5
RxNorm normalized name: Dextrose 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The second group will receive placebo (D5W) as the following~1. Loading dose: 3-5 ml in the first 12-24 hours To be infused over 15 minutes.~2. Maintenance dose: 3-5 ml after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days.
Trial: NCT01331733
Drug: hMG-HP
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02733237
Drug: placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intranasal administration of placebo (40 IU)
Trial: NCT02497612
Drug: Ferroquine SSR97193
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Capsules Route of administration: oral
Trial: NCT00611533
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo equivalent for 6 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.
Trial: NCT00799006
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be given placebo or PF-04620110
Trial: NCT01865188
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental monotherapy doses
Trial: NCT01865188
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator dose
Trial: NCT01200524
Drug: AZD2423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tablet